Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:matinas_biopharma [2023/05/09 06:43]
liam
+++ pharmaceutical_companies:matinas_biopharma [2024/11/10 19:22] (current)
liam [External links]
@@ Line 17: / Line 17: @@
 On April 11, 2022, Matinas and [[BioNTech]] announced a research collaboration "to evaluate a novel delivery technology for [[:mRNA vaccines|mRNA-based vaccines]]."((Zacks Equity Research. (2022, April 12). //Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines.// Nasdaq. https://web.archive.org/web/20220412202120/https://www.nasdaq.com/articles/matinas-mtnb-up-on-deal-with-biontech-for-mrna-vaccines))
-In January 2023, Matinas and [[National Resilience]] "entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids."((Bhargava, A. (2023, January 23). //Matinas BioPharma Provides Business Update and 2023 Strategic Outlook.// Matinas BioPharma Holdings, Inc. http://archive.today/2023.01.31-021839/https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/439/matinas-biopharma-provides-business-update-and-2023)) In early 2023, the company sought funding from the [[:Biomedical Advanced Research and Development Authority]] (BARDA).
+In January 2023, Matinas and [[National Resilience]] "entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids."((Bhargava, A. (2023, January 23). //Matinas BioPharma Provides Business Update and 2023 Strategic Outlook.// Matinas BioPharma Holdings, Inc. http://archive.today/2023.01.31-021839/https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/439/matinas-biopharma-provides-business-update-and-2023)) In early 2023, the company sought funding from the [[:Biomedical Advanced Research and Development Authority]] (BARDA), and continued into its third project with [[Genentech]].
+[[Gilead Sciences]] announced it had ended its partnership with Matinas in January 2023 in order to pursue their own [[:remdesivir]] "pro-drug".((Block, J. (2023, January 31). //Gilead abandons oral version of COVID drug remdesivir with Matinas Biopharma (NYSE:MTNB).// Seeking Alpha. https://web.archive.org/web/20230518231633/https://seekingalpha.com/news/3930004-gilead-abandons-oral-version-of-covid-drug-remdesivir-with-matinas-biopharma))
 ===== Activities =====
 Matinas is running clinical trials for MAT2203, a cryptococcal meningitis treatment, led by principal investigators [[:David Boulware]] and [[:David Meya]].((Matinas BioPharma Nanotechnologies, Inc., & University of Minnesota. (2022, September 15). //Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3.// ClinicalTrials.gov. https://web.archive.org/web/20230509041731/https://clinicaltrials.gov/ct2/show/NCT05541107))
+===== Organization =====
+==== Personnel ====
+^ Name  ^ Position  ^ Notes  ^
+| [[:Jerry Jabbour]]  | Co-founder and CEO((//Jerry Jabbour, Matinas BioPharma Holdings inc: Profile and Biography.// Bloomberg. Retrieved May 18, 2023, from http://archive.today/2023.05.18-225130/https://www.bloomberg.com/profile/person/18631011))  | -  |
+| [[:Abdel Fawzy]]  | Co-founder and Executive VP((//Abdel A. Fawzy, Ph.d. | Matinas Biopharma | United States of America.// OMICS International. Retrieved May 18, 2023, from http://archive.today/2023.05.18-225547/https://biography.omicsonline.org/united-states-of-america/matinas-biopharma/abdel-a-fawzy-phd-1369145))  | -  |
+==== Investors ====
+[[:SternAegis]] invested in Matinas in May 2013.((//Venture Round - MATINAS BIOPHARMA - 2013-05-17 - Crunchbase Funding Round Profile.// Crunchbase. Retrieved May 18, 2023, from https://www.crunchbase.com/funding_round/matinas-biopharma-series-unknown--c2ad135e))
 ===== External links =====
   * [[https://www.matinasbiopharma.com/|Website]]
+  * [[https://wiki.whiteroseintelligence.com/en/Matinas-BioPharma|White Rose Wiki]]